Ace J. Hatch - Concepedia

Author

Ace J. Hatch

Duke Medical Center ORCID

Also Known As

A. Hatch, A.J. Hatch, Ace Hatch, Ace J. Hatch, Ace Joseph Hatch, Alex D. Hatch, Jiang, Chen

Publications

603

Citations

H-Index

Concepts

All Affiliations

Duke Medical Center Duke University University of California, San Francisco Duke University Hospital University of North Carolina at Chapel Hill

About

Ace J. Hatch is an author at Duke Medical Center specializing in medicine, transcriptional regulation, and cell signaling.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	158
2	Natural Sciences	1	1	116
3	Biochemistry	1	1	116
4	Cell Biology	1	1	27
5	Immunology	1	1	15

Ace J. Hatch

Publications

477

Citations

H-Index

Page 1

	Year	Citations
Substrate selection by the proteasome during degradation of protein complexes Sumit Prakash, Tomonao Inobe, Ace J. Hatch, Nature Chemical Biology Protein ChemistryProtein FunctionBiochemistryProtein AssemblyProtein Folding	2008	116
Gene Expression Markers of Efficacy and Resistance to Cetuximab Treatment in Metastatic Colorectal Cancer: Results from CALGB 80203 (Alliance) Stephanie M. Cushman, Chen Jiang, Ace J. Hatch, Clinical Cancer Research	2014	87
Radiogenomic Analysis of Locally Advanced Lung Cancer Based on CT Imaging and Intratreatment Changes in Cell-Free DNA Kyle J. Lafata, Michael N. Corradetti, Junheng Gao, Radiology Imaging Cancer	2021	38
Association of Tumor <i>HER3</i> Messenger RNA Expression With Panitumumab Efficacy in Advanced Colorectal Cancer Jenny F. Seligmann, Ace J. Hatch, Susan D. Richman, JAMA Oncology	2017	29
Prognostic and Predictive Biomarkers in Patients with Metastatic Colorectal Cancer Receiving Regorafenib Yingmiao Liu, Jing Lyu, Kirsten B. Burdett, Molecular Cancer Therapeutics	2020	29
Inositol phosphate multikinase dependent transcriptional control Ace J. Hatch, Audrey R. Odom John, John D. York Advances in Biological Regulation Transcriptional RegulationSignal TransductionMolecular RegulationProtein PhosphorylationGene Expression	2017	27
A Phase I Trial of the IGF-1R Antibody Ganitumab (AMG 479) in Combination with Everolimus (RAD001) and Panitumumab in Patients with Advanced Cancer Gordana Vlahovic, Kellen L. Meadows, Ace J. Hatch, The Oncologist	2018	25
RasGRP1 is a potential biomarker for stratifying anti-EGFR therapy response in colorectal cancer Oghenekevwe M. Gbenedio, Caroline Bonnans, Delphine Grün, JCI Insight	2019	23
Cabozantinib and Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer John H. Strickler, Christel Rushing, Hope E. Uronis, The Oncologist	2021	22
Blood‐based markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from <scp>CALGB</scp> 80203 (Alliance) Ace J. Hatch, Alexander B. Sibley, Mark D. Starr, Cancer Medicine	2016	20

Page 1